EP0859633A2 - Procede de traitement des diabetes - Google Patents
Procede de traitement des diabetesInfo
- Publication number
- EP0859633A2 EP0859633A2 EP97938359A EP97938359A EP0859633A2 EP 0859633 A2 EP0859633 A2 EP 0859633A2 EP 97938359 A EP97938359 A EP 97938359A EP 97938359 A EP97938359 A EP 97938359A EP 0859633 A2 EP0859633 A2 EP 0859633A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- interferon
- cells
- insulin
- cell
- diabetes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/249—Interferons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the instant invention provides for a method for treating type I diabetes comprising intervention of interferon alpha activity.
- the instant invention encompasses methods for treating early type I diabetes comprising administering an effective inhibitory amount of an antisense oligonucleotide directed to the mRNA encoding for interferon- ⁇ . Effective inhibition encompasses the complete or partial inhibition of transcription of the interferon alpha gene, or complete or partial inhibition of translation of the interferon alpha mRNA transcript.
- spontaneously diabetic BB rats are another model system by which early intervention to prevent the effects of interferon, as a means of preventing the development of diabetes can be tested where there is a demonstrated genetic predisposition to develop diabetes.
- the leftward boundary of the promoter is always upstream of the TATA box, a ubiquitous sequence of 7 or 8 bp that lies usually about 20 to 30 bp upstream from the starting point of transc ⁇ ption (Wagner R., Nature (1964) 204, 49).
- Functional IFN mRNA cannot be extracted from unmduced cells. Transc ⁇ ption starts early after induction, the actual time being a function of the inducer-cell system studied. When human lymphoblastoid Namalwa cells are treated with the Sendai virus, IFN ⁇ and IFN ⁇ are produced (Havell E. et al., J. Gen. Virol. (1977) 38, 51).
- the antisense molecule can be a native nucleic acid (DNA or RNA) or a modified nucleic acid.
- modified antisense molecules one can use a phosphorothioate, a methylphosphonate, a PNA (Peptide Nucleic Acid), or any of the modifications commonly practiced ( see Crooke R.M. "In vitro toxicology and pharmacokinetics of antisense oligonucleotides, " 1991 , Anti-Cancer Drug Design, 6, 609-646.)
- the main goal would be to utilize the transgenic techniques or the gene therapy for creating insulin producing cells to demonstrate the transfer the genes necessary to induce an insulin production in cells not used by the organism to produce insulin from said kind of cells.
- the insulin gene may be dormant in the cell being used for the gene transfer and thereby the gene transfer would be to operably introduce the regulatory region of the insulin gene in order to create the insulin production. What is yet to be learned is whether the insulin gene composition necessary for the cell to excrete insulin otherwise would be present, and/or whether other gene products necessary for an actual production and excretion of insulin from the cell would be possible.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US698926 | 1985-02-07 | ||
US69892696A | 1996-08-16 | 1996-08-16 | |
US76029996A | 1996-12-04 | 1996-12-04 | |
US760299 | 1996-12-04 | ||
PCT/US1997/014448 WO1998006431A2 (fr) | 1996-08-16 | 1997-08-15 | Procede de traitement des diabetes |
Publications (1)
Publication Number | Publication Date |
---|---|
EP0859633A2 true EP0859633A2 (fr) | 1998-08-26 |
Family
ID=27106305
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP97938359A Withdrawn EP0859633A2 (fr) | 1996-08-16 | 1997-08-15 | Procede de traitement des diabetes |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP0859633A2 (fr) |
AU (1) | AU4070897A (fr) |
WO (1) | WO1998006431A2 (fr) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2007202840B2 (en) * | 2001-01-09 | 2011-07-28 | Baylor Research Institute | Methods for treating autoimmune diseases in a subject and in vitro diagnostic assays |
WO2006086586A2 (fr) | 2005-02-10 | 2006-08-17 | Baylor Research Institute | Anticorps monoclonaux anti-interferon alpha et procedes d'utilisation |
BRPI0912570B8 (pt) | 2008-05-07 | 2021-05-25 | Argos Therapeutics Inc | anticorpo anti-ifn-alfa humanizado, ou um fragmento de ligação ao antígeno do mesmo, composição terapêutica e seus usos |
US20140242038A1 (en) * | 2011-10-11 | 2014-08-28 | The Trustees Of Columbia University In The City Of New York | Method for generating beta cells |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3005897A1 (de) * | 1980-02-16 | 1981-09-03 | Hoechst Ag, 6000 Frankfurt | Genprodukt eines hoeheren organismus aus einem dieses gen enhtaltenden mikroorganismus |
ATE144149T1 (de) * | 1991-08-30 | 1996-11-15 | Genentech Inc | Therapeutisches verfahren zur behandlung von iddm |
IL106591A (en) * | 1992-09-03 | 2008-03-20 | Yeda Res & Dev | Interferon alpha/beta binding protein, its preparation and pharmaceutical compositions containing it |
AU2466895A (en) * | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
-
1997
- 1997-08-15 EP EP97938359A patent/EP0859633A2/fr not_active Withdrawn
- 1997-08-15 AU AU40708/97A patent/AU4070897A/en not_active Abandoned
- 1997-08-15 WO PCT/US1997/014448 patent/WO1998006431A2/fr not_active Application Discontinuation
Non-Patent Citations (1)
Title |
---|
See references of WO9806431A3 * |
Also Published As
Publication number | Publication date |
---|---|
WO1998006431A3 (fr) | 1998-06-18 |
AU4070897A (en) | 1998-03-06 |
WO1998006431A2 (fr) | 1998-02-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3867033B2 (ja) | 疾患の治療的処置および予防のためにbcl−2を用いる方法 | |
US7438905B2 (en) | Methods of suppressing, treating, or preventing graft rejection with an antibody or a portion thereof that binds to AILIM | |
US5759536A (en) | Use of fas ligand to supress T-lymphocyte-mediated immune responses | |
Yasuda et al. | Local expression of immunoregulatory IL-12p40 gene prolonged syngeneic islet graft survival in diabetic NOD mice. | |
EP0979080B1 (fr) | Procede de modulation d'une reaction immunitaire chez un mammifere infecte par administration transmuqueuse d'un agent de modulation | |
JPH08505373A (ja) | B細胞前駆体刺激因子 | |
US7744894B2 (en) | Method of treating multiple sclerosis and related t-cell initiated tissue destruction by administering HSA/CD24 | |
Tamai et al. | Cloning and expression of flatfish (Paralichthys olivaceus) interferon cDNA | |
Fang et al. | Interleukin-10 promotes resolution of granulomatous experimental autoimmune thyroiditis | |
EP0815252A1 (fr) | Therapie genique utile lors de transplantations et contre les inflammations ou les thromboses | |
WO2002101012A9 (fr) | Regulation de l'expression transgenique suivant une transduction par aav | |
CN112840020B (zh) | 溶瘤病毒及其应用 | |
Larin et al. | Immunotherapy with autologous tumor cells engineered to secrete Tag7/PGRP, an innate immunity recognition molecule | |
WO1998006431A2 (fr) | Procede de traitement des diabetes | |
Ghivizzani et al. | Gene therapy approaches for treating rheumatoid arthritis | |
CN101161676A (zh) | 抑制hiv复制的突变型apobec3g分子及其应用 | |
US6677311B1 (en) | Inducible HSV-TK in transformed cell populations | |
AU697095B2 (en) | Expression of viral decoy proteins under the control of a locus control region and uses thereof | |
JP7374502B2 (ja) | Oca-bペプチドコンジュゲート及び処置方法 | |
US8323963B2 (en) | Construction and use of genes encoding pathogenic epitopes for treatment of autoimmune disease | |
WO1997026325A1 (fr) | Compositions et leurs utilisations pour le transfert de genes retro-regulateurs dans des cellules liees a des reponses inflammatoires | |
WO1997026325A9 (fr) | Compositions et leurs utilisations pour le transfert de genes retro-regulateurs dans des cellules liees a des reponses inflammatoires | |
KR100808925B1 (ko) | 돼지 lag-3 융합 이뮤노글로블린 | |
US20050214290A1 (en) | Methods of blocking tissue destruction by autoreactive T cells | |
ES2575629T3 (es) | Polipéptido del Factor VIII |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
PUAK | Availability of information related to the publication of the international search report |
Free format text: ORIGINAL CODE: 0009015 |
|
AK | Designated contracting states |
Kind code of ref document: A3 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
R17D | Deferred search report published (corrected) |
Effective date: 19991007 |
|
R17D | Deferred search report published (corrected) |
Effective date: 19991008 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20000301 |